CD274 and adenocarcinoma: For patients with NSCLC adenocarcinoma subtype without a targetable mutation, the median DOR with chemotherapy and IO by PDL‐1 status is as follows: 15.1 (PDL‐1 > 50%), 12.9 (PDL‐1 1%–49%), and 10.8 (PDL‐1 < 1%) (41).